Capstone Holding Corp.
CAPS | NASDAQ
$0.40
$0.00 (-0.94%)
Nov 2, 2026, 11:19 AM ET · Market open
Company Profile
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Key Executives
| Name | Position |
|---|---|
| Matthew E. Lipman | CEO, Secretary & Director |
| Edward Schultz | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 01, 2026 | 4 | Filing |
| Apr 01, 2026 | 4 | Filing |
| Apr 01, 2026 | 4 | Filing |
| Mar 31, 2026 | NT 10-K | Filing |
| Feb 17, 2026 | 8-K/A | [Amend] Current Report |
| Feb 12, 2026 | DEF 14C | Filing |
| Jan 30, 2026 | PRE 14C | Filing |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 8-K | Current Report |
| Jan 09, 2026 | 8-K | Current Report |
Capstone Holding Corp.
| Country | United States |
| IPO Date | Jan 28, 1993 |
| Industry | Construction Materials |
| Sector | Basic Materials |
| Employees | 36 |
| CEO | Matthew E. Lipman |
Contact Details
1275 West Washington Street Alsip,
Illinois 60803 United States
Stock Details
| Ticker Symbol | CAPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000887151 |
| CUSIP Number | 14068E208 |
| ISIN Number | US14068E2081 |
| SIC Code | 5030 |
Add to Watchlist
Select watchlists to add or remove CAPS